항정신병약 시장 : 규모, 점유율, 동향 분석, 질환별, 약제별, 치료분류별, 유통채널별, 지역별, 부문 예측(2025-2033년)

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others
• Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)
• First Generation
• Second Generation
• Third Generation
• Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Drug
  • 1.2.3. Therapeutic class
  • 1.2.4. Distribution channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease outlook
  • 2.2.2. Drug outlook
  • 2.2.3. Therapeutic class
  • 2.2.4. Distribution Channel
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Antipsychotic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

• 4.1. Disease Segment Dashboard
• 4.2. Antipsychotic Drugs Market: Disease Movement Analysis
• 4.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.3.1. Schizophrenia
    • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.2. Bipolar Disorder
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.3. Unipolar Depression
    • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.4. Dementia
    • 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.5. Others
    • 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drugs Estimates & Trend Analysis

• 5.1. Drugs Segment Dashboard
• 5.2. Antipsychotic Drugs Market: Drug Movement Analysis
• 5.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Drugs, 2021 to 2033 (USD Million)
  • 5.3.1. Risperidone
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Quetiapine
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Olanzapine
    • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.4. Aripiprazole
    • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.5. Brexpiprazole
    • 5.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.6. Paliperidone Palmitate
    • 5.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.7. Others
    • 5.3.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

• 6.1. Therapeutic Class Segment Dashboard
• 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis
• 6.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Therapeutic Class, 2021 to 2033 (USD Million)
  • 6.3.1. First Generation
    • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Second Generation
    • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Third Generation
    • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Segment Dashboard
• 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis
• 7.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.3.1. Hospital Pharmacies
    • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Retail Pharmacies
    • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Online Pharmacies
    • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2033
• 8.3. Continuous bioprocessing market by Region: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework/ reimbursement structure
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company heat map analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. H. Lundbeck A/S
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Janssen Pharmaceuticals, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Eli Lilly and Company
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. AbbVie, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Teva Pharmaceutical Industries Ltd.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Dr Reddy's Laboratories Ltd.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Sumitomo Pharma Co., Ltd.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Alkermes
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Bristol-Myers Squibb Company
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives